Skip to main content
NCBI home page
Nature Portfolio logoLink to Nature Portfolio
. 2024 Sep 16;38(12):2663–2674. doi: 10.1038/s41375-024-02401-9

Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma

Brandon S Willis 1,#, Kevin Mongeon 1,#, Hannah Dry 1, India L Neveras 1, Nadezda Bryan 1, Meghana Pandya 1, Justine Roderick-Richardson 1, Wendan Xu 2, Li Yang 2, Alan Rosen 1, Corinne Reimer 1, Liliana Tuskova 3, Pavel Klener 3, Jerome T Mettetal 1, Georg Lenz 2, Simon T Barry 4,✉
PMCID: PMC11588655  PMID: 39284898

Abstract

The therapeutic potential of targeting PI3K/AKT/PTEN signalling in B-cell malignancies remains attractive. Whilst PI3K-α/δ inhibitors demonstrate clinical benefit in certain B-cell lymphomas, PI3K signalling inhibitors have been inadequate in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in part, due to treatment related toxicities. Clinically, AKT inhibitors exhibit a differentiated tolerability profile offering an alternative approach for treating patients with B-cell malignancies. To explore how AKT inhibition complements other potential therapeutics in the treatment of DLBCL patients, an in vitro combination screen was conducted across a panel of DLCBL cell lines. The AKT inhibitor, capivasertib, in combination with the BCL-2 inhibitor, venetoclax, produced notable therapeutic benefit in preclinical models of DLBCL. Capivasertib and venetoclax rapidly induced caspase and PARP cleavage in GCB-DLBCL PTEN wildtype cell lines and those harbouring PTEN mutations or reduced PTEN protein, driving prolonged tumour growth inhibition in DLBCL cell line and patient derived xenograft lymphoma models. The addition of the rituximab further deepened the durability of capivasertib and venetoclax responses in a RCHOP refractory DLBCL in vivo models. These findings provide preclinical evidence for the rational treatment combination of AKT and BCL-2 inhibitors using capivasertib and venetoclax respectively alongside anti-CD20 antibody supplementation for treatment of patients with DLBCL.

Subject terms: Preclinical research, Haematological cancer

Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype with approximately 30–40% of cases worldwide [1]. DLBCL is a heterogenous B cell malignancy defined by both genetic and epigenetic alterations that regulate cell growth, survival and differentiation [2]. Generally, DLBCL is transcriptionally subclassified into two major subset types, activated B-cell like (ABC) and germinal centre B-cell like (GCB) derived from distinct originating B cell populations. Genomic analyses have identified distinct subtypes of DLBCL with genetic drivers and signalling pathways that are therapeutically targetable [3]. First line therapy for DLBCL largely consists of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP), or more recently, a modified regimen substituting vincristine for polatuzumab vedotin (pola-R-CHP) [4]. Despite these recent improvements in first line therapies, relapsed/refractory DLBCL patients still require novel treatment regimens.

Activation of the canonical phosphoinositide-(3)-kinase (PI3K), AKT and mammalian target of rapamycin (mTOR) signalling pathway is frequently dysregulated across B-cell malignancies [5]. There are frequent mutations found in PIK3CA and PTEN, including down-regulation of PTEN expression in GCB DLBCL [6]. PI3K-AKT pathway inhibitors show differential activity in ABC- versus GCB-DLBCL subclassifications. ABC-DLBCL, which harbour PIK3CA mutations, is sensitive to PI3Kα and PI3Kδ inhibitors [7–9]. Copanlisib, a pan-PI3K inhibitor with PI3Kα and δ activity has clinical activity in follicular lymphoma and has been evaluated in ABC-DLBCL [10, 11]. Safety concerns associated with long-term treatment limits the utility of PI3K inhibitors such as copanlisib and idelalisib. Modulation of the PI3K signalling axis at distinct pathway nodes such as AKT is feasible using the small molecule pan-AKT inhibitor, capivasertib, which has an acceptable safety profile and shown positive benefit in a Phase III clinical trial and FDA approval in combination with fulvestrant for the treatment of hormone receptor positive breast cancer [12].

Relapsed/refractory GCB-DLBCL has a high incidence of PTEN protein loss [6], and GCB DLBCL cell lines and tumour models are sensitivity to AKT inhibition [7, 13], underscoring the importance of the PI3K-AKT signalling axis in GCB-DLBCL. This is further supported by the observation that combined PI3Kβ/δ and mTORC1/2 inhibition has broad efficacy across preclinical DLBCL models [14]. PI3K-AKT signalling pathways in DLBCL are therefore essential in different subtypes whilst the key pathway node for therapeutic modulation varies amongst subtypes.

R-CHOP is the conventional treatment for patients with DLBCL, along with the recent approval of Pola-R-CHP [4]. Additionally, clinical benefit in patients with various haematological malignancies has been observed using the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax which induces apoptosis [15]. Venetoclax is approved for newly diagnosed and relapse/refractory adult patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma with 17p deletion, and for newly diagnosed acute myeloid leukaemia patients in combination with various hypomethylating agents [16, 17]. In Phase II clinical trial, addition of venetoclax to RCHOP enhanced clinical benefit in high risk DLBCL patients [19]. Preclinically, venetoclax combined with an epigenetic EZH2 inhibitor extended survival benefit of DLBCL PDX mouse models [18, 19]. Finally, venetoclax resistance in DLBCL cell lines associates with AKT signalling activation, suggesting that AKT antagonism could improve venetoclax response [20–23].

Given PI3K-AKT dependency in DLBCL, combination of capivasertib and venetoclax along with an anti-CD20 antibody, rituximab could present a unique therapeutic opportunity for patients with relapse/refractory DLBCL [24–27]. Herein, we provide preclinical evidence of capivasertib and venetoclax combinations along with the addition of rituximab as an attractive, novel treatment regimen for treatment of GCB DLBCL. Specifically, this combination rapidly activates caspases leading to robust tumour cell death driving anti-tumour efficacy in preclinical models of relapse/refractory DLBCL.

Methods

Combination screen

The combination of capivasertib and venetoclax was evaluated in an in vitro DLBCL cell panel proliferation screen as previously published [28]. Cells were seeded between 1000–8000 cells per well in 384-well plate. 24 h after plating cells were treated for 120 h with a 6-point dose response (0.03–3 µM) in a combination matrix (6 × 6) using an Echo 555 acoustic dispenser (Labcyte). Live cells were quantified using an imaging-based assay utilising Sytox Green (ThermoFisher, MA) and saponin (Sigma–Aldrich, MO) to permeabilise the cells. Cell proliferation versus cell death was determine by comparing Day 0 (pre-treatment) and 72 or 120 h (post-treatment). Percentage growth was calculated from the live cell number. Two-dimensional dose response matrix and curve fitting were processed in the combination extension of Genedata Screener 13™ (Genedata AG, Basel,Switzerland) as previously described [28]. Combination activity was calculated using the Loewe dose-additivity model using a synergy score cut-off >5.

Cell line culture and reagents

DNA fingerprinting short tandem repeat authentication of cell lines was performed. Culture media are listed in supplementary Table S1. In caspase-glo 3/7 (Promega, WI) experiments, cells were pre-treated overnight with Q-VD-OPH (50 µM) (Cayman Chemical, MI) or vehicle prior to seeding. Capivasertib (AZD5363) was synthesized at AstraZeneca. Venetoclax was purchased from Medkoo Biosciences (Durham, NC). Generation of stable genetic knockout cell lines using Ribonucleoprotein (RNP) nucleofection was conducted using the NEON electroporation system (Invitrogen, CA). Details on the sgRNAs are captured in supplementary Table S3.

Biomarker analysis

Western blots were performed as previously described [29]. Cells were lysed in Phosphosafe lysis reagent (EMD Millipore, MA) supplemented with 1X HALT Protease and Phosphatase Inhibitor (PPI) Cocktail (Thermo Fisher, MA). A 1% (w/v) SDS, 10% (v/v) glycerol, 0.1 M Tris-HCl (pH 6.8) lysis buffer supplemented with 1:1000 benzonase (Sigma Aldrich, MO) and HALT PPI cocktail was used for protein extraction to probe for BAK and BAX. Horseradish peroxidase–linked secondary antibodies (Cell Signalling Technology, MA) and DETECTED Pierce ECL SuperSignal™ West Pico PLUS Chemiluminescent Substrate or Femto Maximum Sensitivity Substrate (Thermo Fisher, MA) were used to detect immune complexes. Cytochrome c release assay kit was performed according to manufacturer instructions (Abcam, UK). Primary antibodies details are shown in Supplementary Table S2.

In vivo studies ethics approvals

All cell line models were conducted in accordance with the AstraZeneca IACUC (Institutional Animal Care and Use Committee) and reported following the ARRIVE (Animal Research: Reporting In Vivo experiments) guidelines [30]. PDX studies involving the use of laboratory animals conducted in the Center for Experimental Biomodels of the First Faculty of Medicine, Charles University in Prague, Czech Republic, were reviewed and approved by the Institutional Animal Welfare Committee and by the Ministry of Agriculture of the Czech Republic, as well as by the Research and Higher Education section of the Ministry of Education, Youth and Sports of the Czech Republic under the number 592/15 (MSMT-11255/2015-4).

In vivo studies

Cell line derived models were powered according to the AstraZeneca powering tool depending on degree of anti-tumour response anticipated. For PDX models a minimal of 8 animals per group was used. Studies were performed independent of the lead investigators, though compound identity was not blinded. No animals were excluded. Animals were randomized to a consistent mean tumour size per group. All calculations were performed using AstraZeneca. Tumour volume was calculated according to the following formula: π/6 × length × width × height). Statistical analyses. Data shown in graphs are mean ± SEM. Statistical analyses (t-test, multiple comparisons) were performed using GraphPad Prism (version8.4.3). Mouse xenograft models of DLCBL cell lines. Ten million SuDHL4 and WSU-DLCL2 or five million SUDHL5 cells in PBS mixed with 50:50 with Matrigel™ (Beckton Dickinson, Franklin Lakes, NJ, USA) were implanted subcutaneously into the right flank of CB-17 scid female mice. For efficacy studies, growth inhibition from the start of treatment was assessed by comparison of the differences in tumour volume between control and treated groups. Statistical significance was evaluated using a one-tailed, 2-sample t test. Capivasertib was formulated as an oral solution in 10% DMSO/25% Kleptose and dosed 130 mg/kg BID. Venetoclax was formulated as an oral suspension in 60% Phosal 50 PG, 30% polyethylene glycol 400, 10% ethanol. A 4 h gap was provided between each agent with capivasertib dosed first. Long term administration of venetoclax in combination with capivasertib was associated with body weight loss. Dosing holidays were provided and food supplementation when body weight loss was greater than 10–12% for an individual mouse. Body weight loss is because of glucose dysregulation is a common mouse toxicity following inhibition of PI3K-AKT signalling. RCHOP was administered once; Rituxan® (rituximab) 10 mg/kg intraperitoneal, Cytoxan® (cyclophosphamide) 25 mg/kg intraperitoneal, Doxil® (doxorubicin hydrochloride) 3 mg/kg intravenous, Oncovin® (vincristine sulfate) 0.25 mg/kg intravenous, Deltasone® (prednisolone) 0.5 mg/kg by oral gavage, each according to manufacturer’s instructions. Patient Derived Xenograft mouse model of DLBCL. For EBV-negative PDX models, six- to eight-week-old female NOD.Cg-Prkdc severe combined immunodeficiency Il2rgtm1Wjl/SzJ (NSG; Jackson Laboratory, ME, USA) mice were used.

Results

Combined AKT and BCL-2 inhibition is effective in wildtype and PTEN-deficient DLBCL cell lines

Capivasertib monotherapy treatment is effective in GCB DLBCL cell lines and xenograft models [7]. In an attempt to deliver a deeper anti-tumoral response, the activity of capivasertib and venetoclax was explored across a panel of 26 DLBCL cell lines. The panel of 7 ABC, 14 GCB, and 5 unclassified DLBCL cell lines had heterogenous levels of AKT pathway activation, PTEN protein and anti-apoptotic cell death proteins BCL-2, BCL-2-like 1 (BCL-XL) and MCL-1 expression (Fig. 1A). Due to limits in screening capacity, representative lines that capture the DLBCL landscape were selected for a 3-day combination proliferation screen. Monotherapy anti-proliferative responses (GI50) with capivasertib were enriched in PTEN deficient cell lines whereas venetoclax monotherapy resulted in cell death (AC50) in GCB-DLCBL and ABC-DLCBCL subtypes (Fig. 1B). Capivasertib and venetoclax exhibited strong combination activity (determined by Loewe score), predominantly in the GCB-DLCBL subcategory regardless of PTEN status (Fig. 1C), although certain pAKT and BCL-2 positive lines were insensitive to the combination.

Fig. 1. Capivasertib and venetoclax combination results in rapid caspase-mediated cell death in responsive DLBCL models.

Fig. 1

Open in a new tab

A Base line Western blot biomarker profiling of ABC-, GCB-, and unclassified-DLBCL cell models with the OCI-LY1 cell line serving as reference control. B Capivasertib monotherapy anti-proliferative activity (GI50) (μM) and venetoclax monotherapy apoptotic response (Log AC50) (M) across GCB- and ABC-DLBCL cell lines. Order of cell lines is identical to that shown at the bottom of (C). C Loewe synergy scores for the combination of capivasertib and venetoclax in GCB- and ABC-DLBCL cell lines. + and – indicates each cell line’s monotherapy sensitivity to either capivasertib or venetoclax. Order of cell lines identical to that shown in (B). D Time course of caspase-3/7 activity in a cell model unresponsive to the either monotherapy or combination (TMD8), and two responsive models: WSU-DLCL2 (PTEN-mutant; GCB) and SUDHL-4 (PTEN wild-type; GCB) (n = 3/group). E Relative cell proliferation of SUDHL4, WSU-DLCL2 and TMD8 cell lines pretreated overnight with the pan-caspase inhibitor Q-VD-OPH (50 µM) or vehicle and then dosed with compounds for 24 h (n = 5/group; 2-way ANOVA with Sidak’s multiple comparisons ****p < 0.0001). Staurosporine (5 µM) was a positive control for caspase induction and cell killing.

To investigate changes following combination treatment, sensitive PTEN-wild-type (SUDHL-4) and PTEN-deficient (WSU-DLCL2) GCB-DLBCL, as well as an insensitive PTEN wild-type (TMD8, OCI-LY10, U2932), ABC-DLBCL cell lines were evaluated (Fig. 1D, Supp. Fig. 1A). Combination treatment induced rapid induction of caspase 3/7 within 4 h, which was maintained at 24 h in SUDHL-4 and WSU-DLCL2 cell lines whereas the insensitive PTEN wild type cells lacked caspase induction (Fig. 1D, Supplementary Fig. 1A). Interestingly in the PTEN-deficient U2932 cell line whilst combination treatment did not increase caspase 3/7 induction, over long-term treatment a combination benefit was observed, with reduced proliferation versus both monotherapy treatments suggesting acute induction of apoptosis is not necessary for combination benefit (Supp. Fig. 1B). Pharmacological rescue of sensitive GCB-DLBCL cell lines with Q-VD-OPH, a pan-caspase inhibitor, confirmed caspase-mediated cell death (Fig. 1E). In general, the combination induced extensive cell death within 24 h, suggesting that targeting AKT and BCL-2 has potential to enhance DLBCL tumour cell death.

Capivasertib and venetoclax combine to induce caspase-dependent cell death through BAK and BAX

Next, biomarker changes associated with enhanced cell death in the SUDHL-4 and WSU-DLCL2 cells were evaluated. Consistent with the capivasertib mode of action, AKT phosphorylation is enhanced followed by a reduction in phosphorylation of AKT substrates (Fig. 2A) [31–41]. Despite elevated basal AKT activation in PTEN-deficient WSU-DLCL2 cells, capivasertib reduced phosphorylation of S6 kinase in both WSU-DLCL2 and SUDHL-4 cells (Fig. 2A) indicating suppression of PI3K-AKT axis. Modulation of other substrates GSK3β and PRAS40 differed between cell lines indicating downstream signalling heterogeneity. Alterations in phosphorylation of FOXO and 4EBP1 were consistent with inhibition of AKT signalling (Fig. 2A). Venetoclax monotherapy induced minimal PARP1 and caspase-3 cleavage in both WSU-DLCL2 and SUDHL-4 cell lines (Fig. 2A, B). Following combination treatment modulation of AKT signalling emulated capivasertib monotherapy (Fig. 2A). Capivasertib monotherapy had minimal effect on BCL-2 and BCL-XL protein levels or apoptotic biomarkers however, the combination increased PARP1 and caspase-3 cleavage in both GCB-DLBCL cell lines. At certain time points there were reductions in MCL-1 protein levels and MCL-1 cleavage in the SUDHL4 and WSU-DLCL2 cell line however these changes were variable and hence further work is required to determine whether these MCL changes make a contribution to efficacy (Fig. 2B, C) [42, 43]. In the SUDHL4 and WSU-DLCL2 cell lines, combination treatment led to an enhancement in cytochrome c release into the cytoplasm relative to either monotherapy treatments (Supplementary Fig. 2A). As expected, pre-treatment with Q-VD-OPH inhibited combination apoptosis induction (Fig. 2C).

Fig. 2. Combination-mediated induction of cell death markers ablated by BAK/BAX codeletion in responsive DLBCL cell models.

Fig. 2

Open in a new tab

A Western blot profiling of the AKT signalling pathway, known AKT substrates, and (B) apoptotic markers in WSU-DLCL2 and SUDHL-4 when treated with capivasertib and venetoclax monotherapies and in combination at 2and 4 h. C Western blot profiling of apoptotic biomarkers time course of WSU-DLCL2 and SUDHL4 cell lines pretreated with vehicle (DMSO) or Q-VD-OPH (50 µM) then dosed with indicated compounds at 1, 2, and 4 h. D CRISPR/Cas9-mediated of single and double knockout (DKO) of BAK and BAX in WSU-DLCL2 and SUDHL4 cell lines. E Comparison of the induction of cell death markers between BAK/BAX wild-type and DKO WSU-DLCL2 and SUDHL4 cell lines when treated with compounds for 4 h.

Canonical apoptosis induction occurs through mitochondrial outer membrane pore (MOMP) formation with caspase activation preceding PARP1 cleavage and MCL-1 degradation (reviewed in [44–47]). To confirm canonical apoptotic pathway mechanisms, CRISPR/Cas9 gene editing was used to generate BAK and BAX deficient WSU-DLCL2 and SUDHL-4 cell lines with individual and tandem knock out of each gene s (Fig. 2D) [48–50]. Combination treatment of BAK/BAX double knockout (DKO) cells did not induce apoptosis at 4 h, whilst capivasertib reduced AKT signalling (Fig. 2E, Supplementary Fig. 2B). Growth inhibition in BAK/BAX DKO GCB-DLBCL cell lines following combination treatment was equivalent to monotherapy capivasertib (Fig. 3A). Individual knockdown of either BAX or BAK did not block induction of apoptosis (Supplementary Fig. 2B) suggesting cell priming death is mediated through BAX or BAK. Additionally, caspase-8 induction was attenuated in the BAK/BAX DKO GCB-DLBCL cell lines after combination treatment (Fig. 3B, C). These results suggest that combining capivasertib and venetoclax induces cell death by direct effects on mitochondria.

Fig. 3. Combination-mediated induction of cell death markers ablated by BAK/BAX codeletion in responsive DLBCL cell models.

Fig. 3

Open in a new tab

A Growth inhibition of BAK/BAX WT and DKO WSU-DLCL2 and SUDHL4 cells treated as indicated in a 72-hr measured by relative Cell Titer Glo signal growth assay (n = 3/group; 2-way ANOVA with Sidak’s multiple comparisons of the means between WT and DKO in the same treatment group ****p < 0.001). B Relative fold change of caspase-8 activity in BAK/BAX WT and DKO WSU-DLCL2 and SUDHL4 cells treated as indicated for 4 h. Staurosporine (5 µM) was a general positive control for caspase induction and cell killing. n = 3/group; 2-way ANOVA with Sidak’s multiple comparisons of the means between WT and DKO in the same treatment group ****p < 0.001. C Western blot profile of BAK/BAX WT and DKO WSU-DLCL2 and SUDHL4 cells treated with compounds for 4 h in normal glucose-rich growth medium or with medium where glucose is substituted with galactose.

Given AKT signalling regulates metabolism and in particular glucose homeostasis, we hypothesised that metabolic stress may enhance venetoclax activity. We evaluated whether galactose substitution in media could mimic capivasertib mediated inhibition of glucose uptake. Galactose supplementation failed to modulate AKT pathway activation or inhibition of AKT signalling by capivasertib in wildtype and BAK/BAX DKO cell lines. Interestingly, in galactose-substituted medium venetoclax monotherapy treatment resulted in greater induction of cell death markers than in glucose-rich medium, but induction of cell death was not as effective as capivasertib and venetoclax (Fig. 3C). Moreover, cleavage of caspases -3, and -9 was enhanced by combination relative to venetoclax treatment irrespective of medium conditions (Fig. 3C). Again, combination treatment induced cleavage of caspase-9, -3 and -8 (a component of the death-inducing signalling complex canonically associated with the extrinsic apoptosis pathway) and was abrogated upon deletion of BAK and BAX in the presence and absence of galactose (Fig. 3C). Collectively, these data suggest that whilst modulation of glucose uptake and metabolic regulation by capivasertib could enhance apoptosis induction by venetoclax, other AKT dependent mechanisms are contributing to the combination effect.

Capivasertib and venetoclax are efficacious in wildtype and PTEN-null DLBCL tumour xenografts with different doses and schedules

Next the capivasertib and venetoclax combination was validated in vivo. Clinically, capivasertib is administered using an intermittent 4-days on and 3-days off schedule and venetoclax once daily. Consideration of needing to alter dose and schedule in mice with this combination, alternative schedules to evaluate efficacy in vivo was also explored. Mice bearing PTEN-wildtype SUDLH-4 tumour xenografts were treated with both capivasertib 130 mg/kg BID 4-days on/3-days off and venetoclax 100 mg/kg once daily 4-days on/3-days off. Both capivasertib or venetoclax monotherapy treatments gave modest inhibition of relative tumour growth (74% and 46% TGI respectively). Combination treatment gave complete tumour regression (Fig. 4A). Whilst concurrent dosing was highly efficacious, combination treatment on a 4-days on/3-days off schedule exhibited occasional but manageable body weight loss in mice. Therefore, considering that frequent dose alterations of venetoclax are provided clinically, exploration of different dose schedules the combination were evaluated to understand different combination regimens that maintained efficacy whilst minimising potential tolerability issues (Supp. Table S4 and Supplementary Fig. 3A, B). Doses of both drugs varied, however the 4-days on/3-days off capivasertib schedule remained constant whilst frequency of venetoclax varied. Sequential dosing of capivasertib for 4 consecutive days followed by venetoclax for 3 consecutive days reduced combination benefit showing concurrent drug administration drives optimal efficacy (Fig. 4B). Reducing either the dosing frequency or dose level of venetoclax whilst maintaining the clinically relevant capivasertib treatment regimen was assessed. Reduction venetoclax from 100 to 30 mg/kg once daily 4-days on/ 3-days off concurrently with capivasertib drove tumour regressions (Fig. 4C). However, duration of tumour response after treatment cessation was reduced versus the full clinically relevant schedule (data not shown). Frequency reductions of venetoclax administration to 100 mg/kg once daily to day 1 or days 1 and 3 drove tumour regressions with minimal body weight loss (Fig. 4A, B and Supplementary Fig. 3A). However, tumour regrowth was observed 10 days after dosing cessation. Finally, reducing capivasertib to 45 mg/kg 4-days on/3-days off schedule with 100 mg/kg of venetoclax led to a loss of efficacy (Fig. 4C, Supplementary Fig. 3C). Collectively, this suggests that inhibition of AKT is sufficient in priming the combination response, however the induction of cell death can still be achieved with various dose levels of both compounds and frequency of venetoclax treatment.

Fig. 4. Combination of capivasertib with venetoclax induces sustained tumour regression in a PTEN-wildtype SUDHL4 xenograft model.

Fig. 4

Open in a new tab

A Tumour growth curves of CB.17 SCID mice bearing the GCB-DLBCL cell line SuDHL4 xenograft tumours treated with capivasertib (130 mg/kg BID 10/14 4-day on/3-day off) monotherapy, venetoclax (100 mg/kg QD) monotherapy and in combination in accordance with schedules captured in Supplementary Table 1. B Assessment of sustained tumour regression (>60 days post dosing). Both capivasertib and venetoclax were administered on a 4-day on/3-day off schedule relative to combinations using reduced frequency of venetoclax treatment. C Assessment of tumour activity of capivasertib dose reduction versus venetoclax dose reduction on anti-tumour response or tumour regression. Data is represented as geometric mean of tumour volumes and standard error of the mean. *p < 0.05, **p < 0.001, ***p < 0.0001.

Combination treatment reduces growth of human DLBCL PDX models

To further explore this combination in vivo, two DLBCL PDX mouse models that represent relapsed/refractory DLBCL were evaluated. A GCB PDX model, VFN-D7 DHL with low PTEN protein (Fig. 5A) expression harbours both a BCL2 and MYC translocation, hallmarks of double hit lymphoma and the VFN-D1 KTC PDX model has wildtype PTEN protein levels (Fig. 5A), a BCL2 amplification and MYC copy number gain. PDX models were derived from chemotherapy refractory DLBCL patients [51, 52]. These PDX models are established in NSG mice and therefore to accommodate differences in tolerance amongst mouse strains, the drug combination was administered on a modified schedule of 3-days on/4-days off (Supplementary Fig. 3D, E). In both models, the capivasertib and venetoclax combination suppressed tumour growth. (Fig. 5B, C). Therefore, the combination can also deliver improved anti-tumour benefit in vivo in BCL2-positive chemotherapy refractory DLCBL malignancies.

Fig. 5. Combination of capivasertib with venetoclax promotes tumour regression in a PTEN-wildtype and PTEN-null DLBCL PDX mouse models.

Fig. 5

Open in a new tab

A Western blot analysis of PTEN expression in the VFN-D7 and VFN-D1_KTC human DLBCL PDX models. B Tumour growth curves of NSG mice bearing tumours with the double-hit GCB DLBCL PDX model, VFN-D7 or (C) the non-GCB DLCBL PTEN deficient PDX model, VFN-D1_KTC treated with capivasertib on a slightly modified schedule (130 mg/kg BID 10/14 3-day on/4-day off) monotherapy, venetoclax (100 mg/kg QD) and in combination with both agents on 3-day on/4-day off schedule. Comparison of combination treatment tumour regression compared to either monotherapy groups. Data is represented as arithmetic mean and standard error of the mean. *p < 0.05, **p < 0.001, ***p < 0.0001.

AKT and BCL-2 inhibition combines with CD20 antagonism and overcomes RCHOP resistance

Next, we evaluated whether antagonising CD20 using rituximab could further the enhance combination response in PTEN-wildtype SUDHL4, PTEN low protein SUDHL5, and PTEN-null WSU-DLCL2 xenograft models. The triple regimen consisted of capivasertib on 4-day/3-day off schedule, venetoclax given twice weekly and rituximab given twice weekly. In the SUDHL4 xenograft model, the triple combination of capivasertib, venetoclax and rituximab achieved superior efficacy relative to monotherapy and combination arms (Fig. 6A, Supplementary Fig. 3F). Similarly, superior, continuous efficacy was observed in the SUDHL5 xenograft model after a single week following the triple drug regimen exemplifying the anti-tumoral response of this combination (Fig. 6B, Supplementary Fig. 3G). In WSU-DLCL2 xenograft model, the triple regimen resulted in long-term durable responses relative to the combination capivasertib and venetoclax (Fig. 6C, D, Supplementary Fig. 3H). Lastly, given that most DLBCL patients receive RCHOP therapy, we sought to determine whether the triple regimen has potential to be remain active in tumours progressing on RCHOP therapy. Mice bearing WSU-DLCL2 tumours were treated with RCHOP then during tumour progression, mice received the triple regimen which led to rapid tumour regression with kinetics similar to RCHOP naïve DLBCL tumour xenograft models (Fig. 6E, Supplementary Fig. 3J). Collectively, these data suggests that treatment with capivasertib and venetoclax can be further enhanced with anti-CD20 treatment and can be therapeutic in RCHOP resistant setting of DLBCL.

Fig. 6. Combination of capivasertib, venetoclax and rituximab promotes tumour regression in GCB-DLBCL cell line xenograft models and in a RHCOP resistant DLBCL xenograft model.

Fig. 6

Open in a new tab

Assessment of tumour regressions following addition of once weekly rituximab to capivasertib and venetoclax relative to the capivasertib and venetoclax combination on 4-day on/3-day off schedule. A, B Tumour growth curves of CB.17 SCID mice bearing with the GCB-DLBCL cell line (A) SUDHL4 and (B) SUDHL5 xenograft models treated with capivasertib (130 mg/kg BID 10/14 4-day on/3-day off) monotherapy, venetoclax (100 mg/kg QD) monotherapy or rituximab (10 mg/kg 2QW) monotherapy and in combination in accordance with schedules shown in Supplementary Table 1. C Comparison of initial tumour response and tumour regression following the triple combination of capivasertib, venetoclax and rituximab in the WSU-DLCL2 xenograft model relative to the doublet combinations and RCHOP (10 mg/kg rituximab 2QW, 25 mg/kg cyclophosphamide once IP, 3 mg/kg doxorubicin hydrochloride once IV, 0.25 mg/kg vincristine sulphate once IV and 0.5 mg/kg prednisone QD5 PO) treated as indicated (see Supp. Table S4). D Assessment of the sustained tumour regressions in the capivasertib venetoclax versus capivasertib venetoclax rituximab groups. E Tumours from the RCHOP treated group shown in (C) that were resistant to treatment (purple dots) were retreated with the capivasertib, venetoclax and rituximab triplet (yellow dots) and tumour regression assessed. All data is represented as geometric mean of tumour volumes and standard error of the mean (*p < 0.05, **p < 0.001, ***p < 0.0001).

Discussion

Here we show for the first time that combination of capivasertib and venetoclax has potential to provide broad activity in PTEN-wildtype and PTEN-deficient DLBCL preclinical models. This combination causes death of DLBCL cell lines in vitro and is highly efficacious in various lymphoma models in vivo. Concurrent dosing of capivasertib and venetoclax is necessary for optimal anti-tumoral activity and more importantly, we found that combination efficacy and disease control persists following adjustments to either dose level or frequency of venetoclax. Although reducing frequency of venetoclax treatment slightly reduced overall disease control in certain models, addition of rituximab restored maximal efficacy and promoted durable tumour regressions. Whilst directly targeting PI3K demonstrates clinical efficacy in haematological disorders, long-term treatment leads to toxicity issues thereby limiting therapeutic benefit [53]. AKT inhibitors offer an alternative approach to target downstream of PI3K, thus bypassing clinical tolerability issues, particularly in drug combination settings.

The PI3K-AKT pathway provides differential growth signals in DLBCL, however different subsets of disease are impacted by targeting different nodes in the pathway [7, 13]. Monotherapy treatment with PI3Kα/δ inhibitors reduces growth of ABC-DLBCL cell lines and tumour models, whilst monotherapy AKT inhibition in effective in PTEN null GCB DLBCL [7, 9]. Comprehensive inhibition of PI3K-AKT-mTOR signalling with the combination of mTORC1/2 and PI3Kβ inhibitors is effective in DLBCL cell lines of different subtypes [8, 29]. However, for the capivasertib venetoclax combination it was not possible to identify a specific subtype where the combination is more active, nonetheless broad anti-tumoral activity was seen in GCB-DLBCL models. PTEN protein loss is associated with GCB tumours [6, 7, 29] however, GCB-DLBCL PTEN wildtype models are also sensitive to combination treatment. Additionally, in the few ABC-DLBCL cells lines analysed, minimal activity was observed. It is however possible that combination activity is restricted to BCL2 positive lymphomas. Additional studies are necessary to refine patient selection strategies, although the data presented here suggest GCB-DLBCL would have the best outcomes with this combination. It is worth noting, activation of AKT signalling and expression of BCL2 fails to accurately predict combination sensitivity. For example, capivasertib activity is seen in the OCI-LY7 model that has lower levels of AKT signalling. Conversely, a lack of combination response could reflect other mutational drivers, or cellular factors that antagonise venetoclax activity. It is not clear what effect the combination of capivasertib and venetoclax has on other B-cell lineages, and whether it would mimic the B-cell depleting effects of rituximab.

AKT monotherapy activity in PTEN protein deficient solid and haematological tumour cell lines is expected, as well as in tumour with activating alteration in PIK3CA and AKT1. However, capivasertib can deliver monotherapy and combination activity beyond tumours with alterations in PTEN, PIK3CA or AKT1 [25, 53–55]. This is consistent with PI3K signalling regulating cell cycle and proliferation, AKT regulation of apoptosis, cholesterol biosynthesis, glucose metabolism, and gene expression [56–59]. This heterogeneity in dependency on different PI3K-AKT-mTOR signalling nodes in DLBCL suggests whilst the PI3K-AKT signalling pathway is critically important, the mechanism may vary between cell lines [7, 29].

Mechanistic studies in cell lines suggest that the combination drives cell death primarily through the intrinsic apoptotic pathway via MOMP formation, which engages caspase-8 and commonly initiates the extrinsic apoptosis pathway. This is accomplished without any intrinsic crosstalk between AKT signalling and intrinsic apoptosis pathways. A similar effect is observed in PTEN null breast cancer cell lines where AKT inhibition combines with the MCL-1 inhibitor AZD5991 to increase cell death independent of upstream PI3K pathway regulation [60]. Targeting PI3K, AKT or mTORC2 has been a proposed strategy to sensitize malignancies to BH3-mimetics [20, 22, 56, 61–64]. That capivasertib and venetoclax activity can be partially replicated with venetoclax monotherapy in galactose-substituted culture medium suggests that in part AKT inhibition may prime apoptosis through regulation of cellular metabolism. However, this does not wholly explain the combination response as venetoclax treatment in galactose-supplemented medium did not result in comparable changes in apoptotic caspase activity implying simply modulating glucose uptake is not sufficient to replicate the combination activity of capivasertib and venetoclax. Capivasertib monotherapy led to modest Mcl-1 degradation which was more evident in the combination with venetoclax. Again, this was not apparent following galactose supplementation. This may imply that AKT activity has some effect on or regulates Mcl-1 stability although the change in MCL-1 protein levels was modest and variable [22, 63]. However, we did not observe general regulation of BAD or BIM proteins or other regulators apoptosis. It is possible that modest reduction of Mcl-1 expression along with Bcl-2 inhibition may contribute to enhanced killing capacity by the combination and reduce a potential resistance mechanism [43, 65, 66].

Combining the PI3Kα/δ copanlisib and venetoclax has activity in haematological cancers, AML, MCL and DLBCL, however the mechanistic drivers of anti-tumoral activity remains elusive [9]. In AML cells combining the AKT inhibitor ipatasertib (GDC-0068) with venetoclax [67], resulted in cell death through BAX, with BAX deletion preventing cell death. This is possibly through direct phosphorylation of BAX by AKT [68] increasing association with the mitochondria, however in our study deleting BAX had minimal effect on combination sensitivity. Ipatasertib can induce apoptosis in cell lines through PUMA regulation however no evidence of an effect on PUMA in PTEN deficient tumour cells (data not shown) [69]. Interestingly, in PTEN deficient breast lines, synergy between the PI3Kβ inhibitor AZD8186 or capivasertib and AZD5991 (Mcl-1 inhibitor) depends on BAK and is differentiated from the effects in other studies and may indicate that sensitivity can be modulated through both BAK and BAX depending on context, perhaps through non-canonical mechanisms of regulation. An alternate hypothesis is that AKT pathway inhibition induces mitochondrial stress, priming loading of BAK (or BAX) complexes to the mitochondrial membrane with oligomerisation and lysis then triggered by the addition of the MCL1 inhibition. Finally modest cytochrome c leakage from the mitochondria either through PI3K pathway inhibition could be augmented using the combination of capivasertib and venetoclax.

In summary, we show here that combinations of capivasertib, venetoclax and rituximab are highly active in GCB DLBCL models. The combination activity can be achieved with flexible dosing of venetoclax allows potential to modified dose and schedule clinically to manage tolerability. Given the clinical challenges associated with PI3K inhibitors in haematological disease, capivasertib represents a novel approach to target the PI3K-AKT signalling axis with a different tolerability profile. Moreover, targeting AKT has the potential to combine with other relevant targeted therapies to improve response in subsets of DLBCL. The combination of capivasertib and venetoclax with addition of a CD20 antagonist is a potential therapeutic regimen for clinical evaluation in patients with relapsed/refractory DLCBL.

Supplementary information

Supp Materials and Fig. Legends (86.1KB, docx)
Supp Figures (1.9MB, pdf)

Acknowledgements

We would like to thank the in vivo AST group at Gatehouse Park for support with in vivo studies. PK was funded by Ministry of Health of the Czech Republic grant AZV NU21-03-00386, all rights reserved, and National Institute for Cancer Research (EXCELES) LX22NPO5102. Capivasertib was discovered by AstraZeneca subsequent to a collaboration with Astex Therapeutics (and its collaboration with the Institute of Cancer Research and Cancer Research Technology Limited).

Author contributions

B.W. wrote the paper, supervised, designed, or provided experimental interpretation. S.T.B. wrote the paper, supervised, designed, or provided experimental interpretation. K.M. wrote the paper, generated, analyzed and interpreted data. G.L. wrote the paper, supervised, designed, or provided experimental interpretation. P.K. wrote the paper, supervised, designed, or provided experimental interpretation. J.M. supervised, designed, or provided experimental interpretation. C.R. supervised, designed, or provided experimental interpretation. H.D. generated, analyzed and interpreted data. I.N. generated, analyzed and interpreted data. W.X. generated, analyzed and interpreted data. Y.L. generated, analyzed and interpreted data. N.B. generated, analyzed and interpreted data. M.P. generated, analyzed and interpreted data. J.R.R. generated, analyzed and interpreted data. A.L. generated, analyzed and interpreted data. L.T. generated, analyzed and interpreted data. All authors commented on the manuscript.

Data availability

Reagents and data can be accessed as appropriate by contacting simon.t.barry@astrazeneca.com.

Competing interests

B.W., K.M., H.D., I.N., A.R., M.P., N.B., J.R.R., C.R., J.M., and S.B. are current or former AstraZeneca employees and shareholders.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Brandon S. Willis, Kevin Mongeon.

Supplementary information

The online version contains supplementary material available at 10.1038/s41375-024-02401-9.

References

  • 1.Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020;37:551–68.e14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Roschewski M, Phelan JD, Wilson WH. Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma. Cancer J. 2020;26:195–205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N. Engl J Med. 2022;386:351–63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, et al. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol. 2017;187:1700–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Pfeifer M, Lenz G. PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma. Cell Cycle. 2013;12:3347–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017;130:310–22. [DOI] [PubMed] [Google Scholar]
  • 8.Pongas GN, Annunziata CM, Staudt LM. PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma. Oncotarget. 2017;8:81794–802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013;23:826–38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28:2169–78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Lenz G, Hawkes E, Verhoef G, Haioun C, Thye Lim S, Seog Heo D, et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia. 2020;34:2184–97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N. Engl J Med. 2023;388:2058–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Ezell SA, Wang S, Bihani T, Lai Z, Grosskurth SE, Tepsuporn S, et al. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma. Oncotarget. 2016;7:9163–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Xu W, Berning P, Lenz G. Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma. Blood. 2021;138:1110–9. [DOI] [PubMed] [Google Scholar]
  • 15.Cory S, Roberts AW, Colman PM, Adams JM. Targeting BCL-2-like Proteins to Kill Cancer Cells. Trends Cancer. 2016;2:443–60. [DOI] [PubMed] [Google Scholar]
  • 16.DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N. Engl J Med. 2020;383:617–29. [DOI] [PubMed] [Google Scholar]
  • 17.Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–78. [DOI] [PubMed] [Google Scholar]
  • 18.Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, et al. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Adv. 2020;4:5226–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illes A, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137:600–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M, et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2008;7:3265–74. [DOI] [PubMed] [Google Scholar]
  • 22.Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, Plas DR, et al. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res. 2011;71:5204–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget. 2015;6:35202–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Davies AJ. Precision Medicine in DLBCL: Are We There Yet? J Clin Oncol. 2021;39:1314–6. [DOI] [PubMed] [Google Scholar]
  • 25.Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012;11:873–87. [DOI] [PubMed] [Google Scholar]
  • 26.Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8. [DOI] [PubMed] [Google Scholar]
  • 27.Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90:2188–95. [PubMed] [Google Scholar]
  • 28.Crafter C, Vincent JP, Tang E, Dudley P, James NH, Klinowska T, et al. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models. Int J Oncol. 2015;47:446–54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Xu W, Berning P, Erdmann T, Grau M, Bettazova N, Zapukhlyak M, et al. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kbeta/delta blockage in diffuse large B-cell lymphoma. Leukemia. 2023;37:178–89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. J Pharm Pharmacother. 2010;1:94–99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell. 1999;96:857–68. [DOI] [PubMed] [Google Scholar]
  • 32.Cross DAE, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785–9. [DOI] [PubMed] [Google Scholar]
  • 33.Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, Birnbaum MJ, et al. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem. 2003;278:10189–94. [DOI] [PubMed] [Google Scholar]
  • 34.Rena G, Guo S, Cichy SC, Unterman TG, Cohen P. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem. 1999;274:17179–83. [DOI] [PubMed] [Google Scholar]
  • 35.Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996;15:6541–51. [PMC free article] [PubMed] [Google Scholar]
  • 36.Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol. 1997;7:261–9. [DOI] [PubMed] [Google Scholar]
  • 37.Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem. 2005;280:40406–16. [DOI] [PubMed] [Google Scholar]
  • 38.Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006;127:125–37. [DOI] [PubMed] [Google Scholar]
  • 39.Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–101. [DOI] [PubMed] [Google Scholar]
  • 40.Scheid MP, Marignani PA, Woodgett JR. Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol. 2002;22:6247–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5- trisphosphate-dependent activation of protein kinase B. Science. 1998;279:710–4. [DOI] [PubMed] [Google Scholar]
  • 42.Herrant M, Jacquel A, Marchetti S, Belhacene N, Colosetti P, Luciano F, et al. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene. 2004;23:7863–73. [DOI] [PubMed] [Google Scholar]
  • 43.Weng C, Li Y, Xu D, Shi Y, Tang H. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem. 2005;280:10491–10500. [DOI] [PubMed] [Google Scholar]
  • 44.Chipuk JE, Bouchier-Hayes L, Green DR. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ. 2006;13:1396–402. [DOI] [PubMed] [Google Scholar]
  • 45.Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 2008;18:157–64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25:65–80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11:621–32. [DOI] [PubMed] [Google Scholar]
  • 48.Cost GJ, Freyvert Y, Vafiadis A, Santiago Y, Miller JC, Rebar E, et al. BAK and BAX deletion using zinc-finger nucleases yields apoptosis-resistant CHO cells. Biotechnol Bioeng. 2010;105:330–40. [DOI] [PubMed] [Google Scholar]
  • 49.Lindsten T, Ross AJ, King A, Zong W-X, Rathmell JC, Shiels HA, et al. The Combined Functions of Proapoptotic Bcl-2 Family Members Bak and Bax Are Essential for Normal Development of Multiple Tissues. Mol Cell. 2000;6:1389–99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Wei MC, Zong WX, Cheng EHY, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Jaksa R, Karolova J, Svaton M, Kazantsev D, Grajciarova M, Pokorna E, et al. Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas. Lab Invest. 2022;102:957–65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Klanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J, et al. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Clin Cancer Res. 2016;22:1138–49. [DOI] [PubMed] [Google Scholar]
  • 53.Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, et al. Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ Breast Cancer. 2023;9:64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Eberlein C, Williamson SC, Hopcroft L, Ros S, Moss JI, Kerr J, et al. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. Br J Cancer. 2024;130:1377–87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Lynch JT, McEwen R, Crafter C, McDermott U, Garnett MJ, Barry ST, et al. Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen. Oncotarget. 2016;7:22128–39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, et al. Targeted inhibition of PI3Kalpha/delta is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 2019;133:70–80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Lynch JT, Polanska UM, Delpuech O, Hancox U, Trinidad AG, Michopoulos F, et al. Inhibiting PI3Kbeta with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors. Clin Cancer Res. 2017;23:7584–95. [DOI] [PubMed] [Google Scholar]
  • 58.Lynch JT, Polanska UM, Hancox U, Delpuech O, Maynard J, Trigwell C, et al. Combined Inhibition of PI3Kbeta and mTOR Inhibits Growth of PTEN-null Tumors. Mol Cancer Ther. 2018;17:2309–19. [DOI] [PubMed] [Google Scholar]
  • 59.Fontana F, Giannitti G, Marchesi S, Limonta P. The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer. Int J Biol Sci. 2024;20:3113–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Dunn S, Eberlein C, Yu J, Gris-Oliver A, Ong SH, Yelland U, et al. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kbeta/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. Oncogene. 2022;41:5046–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Paulus A, Akhtar S, Yousaf H, Manna A, Paulus SM, Bashir Y, et al. Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J. 2017;7:e565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, et al. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clin Cancer Res. 2018;24:3967–80. [DOI] [PubMed] [Google Scholar]
  • 63.Scott Lee J, Tang SS, Ortiz V, Vo TT, Fruman DA. MCL-1-independent mechanisms of synergy between dual PI3K/ mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget. 2015;6:35202–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Spender LC, Inman GJ. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt’s lymphoma cells to BH3 mimetics. Mol Cancer Res. 2012;10:347–59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Phillips DC, Xiao Y, Lam LT, Litvinovich E, Roberts-Rapp L, Souers AJ, et al. Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 2015;5:e368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9:5341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, Kmieciak M, et al. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells. Cancer Res. 2018;78:3075–86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Kale J, Kutuk O, Brito GC, Andrews TS, Leber B, Letai A, et al. Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Rep. 2018;19:e45235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Sun L, Huang Y, Liu Y, Zhao Y, He X, Zhang L, et al. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis. Cell death Dis. 2018;9:911. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supp Materials and Fig. Legends (86.1KB, docx)
Supp Figures (1.9MB, pdf)

Data Availability Statement

Reagents and data can be accessed as appropriate by contacting simon.t.barry@astrazeneca.com.

Articles from Leukemia are provided here courtesy of Nature Publishing Group

RESOURCES